Wilshire Laboratories (Private) Limited
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical and nutraceutical manufacturer with four decades of operations and a portfolio serving Pakistan and international markets.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Wilshire Labs (Pvt) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- 124/1, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore, Pakistan
- Website
- wilshirelabs.com ↗
- Phone
- +92 111 999 555
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| BAXID | Voriconazole | 50 mg | Tablet | 10s | 088593 | PKR 690.75 | PKR 69.08/tablet | 13% below median |
| BAXID | Voriconazole | 200 mg | Tablet | 10s | 088594 | PKR 1,899.55 | PKR 189.96/tablet | 8% below median |
| BENZIM | Omeprazole | 40 mg | Tablet | 14s | 044599 | PKR 447.34 | PKR 31.95/tablet | 9% below median |
| Benzim | Omeprazole | 40 mg | Injection | 1's | 071375 | PKR 447.34 | PKR 447.34/vial/unit | 20% below median |
| CAPRINZA | Amlodipine | 5 mg | Tablet | 2x10's | 067736 | PKR 146.49 | PKR 7.32/tablet | 32% below median |
| CLOFINA | Clomifene citrate | 50 mg | Tablet | 10s | 099816 | PKR 290.77 | PKR 29.08/tablet | 31% below median |
| Devire | Tenofovir disoproxil | 300 mg | Tablet | 30s | 085839 | PKR 5,769.43 | PKR 192.31/tablet | 14% below median |
| DMARD | Methotrexate | 2.5 mg | Tablet | 10x10 | 052816 | PKR 886.32 | PKR 8.86/tablet | 71% below median |
| EFEDSource observed | Ephedrine | — | Injection | 5s | 080064Official source ↗ | No indexed price | — | — |
| ENESTRA | Anastrozole | 1 mg | Tablet | 30s | 096441 | PKR 8,359.53 | PKR 278.65/tablet | 18% below median |
| FALCINIL | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 040944 | PKR 535.14 | PKR 33.45/tablet | 16% below median |
| FANSI PLUS | Artesunate + Sulfadoxine + Pyrimethamine | 100 mg + 500 mg + 25 mg | Tablet | 3+6's | 057496 | PKR 175.59 | — | No comparator |
| FANSIWIL | Sulfadoxine + Pyrimethamine | 500 mg + 25 mg | Tablet | 10's | 026297 | PKR 62.15 | PKR 6.22/tablet | 34% below median |
| FLEXIFLOW | Clopidogrel | 75 mg | Tablet | 14's | 035509 | PKR 298.11 | PKR 21.29/tablet | 22% below median |
| FLEXIFLOW | Clopidogrel | 75 mg | Tablet | 10s | 035509 | PKR 212.93 | PKR 21.29/tablet | 22% below median |
| FLEXIFLOW | Clopidogrel | 300 mg | Tablet | 10's | 037321 | PKR 608.38 | PKR 60.84/tablet | 9% below median |
| FUTINE | Fluoxetine | 20 mg | Tablet | 10's | 041772 | PKR 123.55 | PKR 12.36/tablet | Near median |
| GLYFORM | Metformin | 500 mg | Tablet | 50's | 015872 | PKR 153.41 | PKR 3.07/tablet | 14% above median |
| GRYTIL | Entecavir | 1 mg | Tablet | 3x10's | 086345 | PKR 18,116.00 | PKR 603.87/tablet | Near median |
| HISTANIL | Loratadine | 10 mg | Tablet | 30s | 026294 | PKR 566.84 | PKR 18.89/tablet | 32% above median |
| HISTANIL | Loratadine | 10 mg | Tablet | 1x10's | 026294 | PKR 209.09 | PKR 20.91/tablet | 46% above median |
| JEMVESTASource observed | Empagliflozin | — | Tablet | 14s | 107162Official source ↗ | No indexed price | — | — |
| JEMVESTASource observed | Empagliflozin | — | Tablet | 14s | 107163Official source ↗ | No indexed price | — | — |
| JEMVESTA Tablet EmpagliflozinSource observed | — | — | — | 14s | 107162Official source ↗ | No indexed price | — | — |
| JEMVESTA Tablet EmpagliflozinSource observed | — | — | — | 14s | 107163Official source ↗ | No indexed price | — | — |
| KIZROSource observed | Artemether | — | Injection | 1's x1ml | 084446Official source ↗ | No indexed price | — | — |
| KIZROSource observed | Artemether | — | Injection | 1's x1ml | 084446Official source ↗ | No indexed price | — | — |
| Lignocaine | Lidocaine | 1% w/v (10 mg/mL) | Injection | 1's | 074295 | PKR 3.19 | PKR 3.19/vial/unit | No comparator |
| LISCOWIL | Colistimethate sodium | 1 MIU | Injection | 1s | 116450 | PKR 2,118.91 | PKR 2,118.91/vial/unit | 77% above median |
| MELBEK | Zinc sulfate | 20 mg elemental zinc/5 mL | Suspension | 60ml | 054007 | PKR 89.47 | PKR 1.49/mL | Near median |
| MELBEK | Zinc sulfate | 20 mg elemental zinc/5 mL | Suspension | 120ml | 054007 | PKR 178.94 | PKR 1.49/mL | Near median |
| MELBEK D | Zinc sulfate | 20 mg | Tablet | 30's | 057497 | PKR 268.40 | PKR 8.95/tablet | 13% below median |
| MELBEK Elemental | Zinc | 20 mg | Suspension | 100ml | 054007 | PKR 134.20 | PKR 1.34/mL | No comparator |
| MICARDIM-AM | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 30s | 102469 | PKR 1,424.56 | PKR 47.49/tablet | 30% below median |
| MICARDIM-AM | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 10s | 102469 | PKR 475.33 | PKR 47.53/tablet | 30% below median |
| MICARDIM-AM | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 20s | 102469 | PKR 950.66 | PKR 47.53/tablet | 30% below median |
| MICARDIM-AM | Telmisartan + Amlodipine | 40 mg + 5 mg | Tablet | 14s | 102470 | PKR 496.94 | PKR 35.50/tablet | 30% below median |
| MICARDIM-HC | Telmisartan + Hydrochlorothiazide | 40 mg + 12.5 mg | Tablet | 28s | 102471 | PKR 848.40 | PKR 30.30/tablet | 31% below median |
| MICARDIM-HC | Telmisartan + Hydrochlorothiazide | 40 mg + 12.5 mg | Tablet | 14s | 102471 | PKR 446.52 | PKR 31.89/tablet | 27% below median |
| MICARDIM-HC | Telmisartan + Hydrochlorothiazide | 80 mg + 25 mg | Tablet | 28s | 102472 | PKR 1,606.05 | PKR 57.36/tablet | 32% below median |
| MICARDIM-HC | Telmisartan + Hydrochlorothiazide | 80 mg + 25 mg | Tablet | 14s | 102472 | PKR 849.84 | PKR 60.70/tablet | 29% below median |
| MICARDIM-HC | Telmisartan + Hydrochlorothiazide | 80 mg + 12.5 mg | Tablet | 28s | 102476 | PKR 1,598.84 | PKR 57.10/tablet | 30% below median |
| MICARDIM-HC | Telmisartan + Hydrochlorothiazide | 80 mg + 12.5 mg | Tablet | 14s | 102476 | PKR 842.63 | PKR 60.19/tablet | 26% below median |
| MODLIP | Simvastatin | 10 mg | Tablet | 1x10's | 034401 | PKR 277.60 | PKR 27.76/tablet | Near median |
| MODLIP | Simvastatin | 20 mg | Tablet | 1x10's | 034402 | PKR 418.07 | PKR 41.81/tablet | 11% below median |
| MODLIP | Simvastatin | 40 mg | Tablet | 1x10's | 034403 | PKR 694.00 | PKR 69.40/tablet | Near median |
| NAMSAL | Sodium chloride | 0.009 g/mL | Injection | 5ml | 099817 | PKR 20.71 | PKR 4.14/mL | No comparator |
| NEO-RISPSource observed | Risperidone | — | Tablet | 10's | 085184Official source ↗ | No indexed price | — | — |
| NEO-RISP | Risperidone | 2 mg | Tablet | 10's | 085185 | PKR 326.10 | PKR 32.61/tablet | 12% below median |
| NEO-RISP | Risperidone | 3 mg | Film-coated tablet | 10's | 085186 | PKR 501.69 | PKR 50.17/tablet | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.